Hemolytic Uremic Syndrome

Hemolytic Uremic Syndrome (HUS) is a rare but life-threatening clinical triad characterized by microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury (AKI). It is the leading cause of acute renal failure in children. Most cases are triggered by an enteric infection with Shiga toxin-producing Escherichia coli (STEC), typically following a prodrome of bloody diarrhea. A secondary, rarer form known as atypical HUS (aHUS) results from uncontrolled activation of the alternative complement pathway due to genetic mutations or autoantibodies.

The etiology varies by subtype:

1. Typical HUS (STEC-HUS): Caused by Shiga toxin-producing bacteria, most commonly *E. coli

1. Atypical HUS (aHUS): Caused by genetic mutations in complement regulatory proteins (Factor H, Factor I, Membrane Cofactor Protein) or acquired antibodies against Factor H.


2. Secondary HUS: Associated with Streptococcus pneumoniae infection, certain medications (quinine, cyclosporine, chemotherapy), pregnancy, or systemic diseases like SLE.

The hallmark of HUS is systemic endothelial cell injury, primarily within the renal microvasculature. In STEC-HUS, Shiga toxin binds to the globotriaosylceramide (Gb3) receptor on endothelial cells, leading to protein synthesis inhibition and cell death. This damage triggers a pro-thrombotic state, resulting in fibrin and platelet thrombi in small vessels. As red blood cells pass through these partially occluded vessels, they undergo mechanical fragmentation, creating schistocytes (hemolysis). Platelets are consumed within these thrombi, leading to thrombocytopenia. The localized microthrombi in the glomeruli cause a sudden drop in glomerular filtration rate (GFR) and subsequent renal failure.

STEC-HUS primarily affects children under age 5, with an incidence of approximately 2 per 100,000 person-years. Outbreaks often occur in summer months. Atypical HUS is much rarer, affecting both children and adults, and carries a higher risk of chronicity.

• Age (young children and the elderly).
• Consumption of undercooked ground meat or unpasteurized dairy.
• Exposure to farm animals or contaminated recreational water.
• Genetic mutations in complement-regulating genes (for aHUS).
• Recent gastrointestinal infection.

A. Early Symptoms

• Abdominal pain and cramping.


• Vomiting.


• Watery or bloody diarrhea. B. Common Symptoms


• Pallor (due to anemia).


• Fatigue and lethargy.


• Petichiae or bruising (due to low platelets).


• Oliguria (decreased urine output). C. Advanced Symptoms


• Edema (swelling in limbs/face).


• Hypertension.


• Jaundice.


• Confusion or irritability. D. Emergency Symptoms


• Seizures or stroke-like symptoms.


• Anuria (total lack of urine).


• Severe respiratory distress.


• Coma.

• Vital Signs: Tachycardia, tachypnea, and hypertension are common.
• Inspection: Pale conjunctiva and skin, jaundice, petechiae, and peripheral edema.
• Palpation: Abdominal tenderness; occasionally hepatosplenomegaly.
• Auscultation: Gallop rhythm if fluid overload/heart failure is present; crackles in lungs if pulmonary edema occurs.

A. Clinical Assessment: History of diarrheal illness and physical signs of dehydration or fluid overload.
B. Laboratory Testing: Essential for confirming the triad (Anemia, Thrombocytopenia, AKI).
C. Imaging Studies: Renal ultrasound to assess kidney size and exclude other causes of renal failure.
D. Functional Tests: Monitoring of urine output and blood pressure.
E. Biopsy Findings: Kidney biopsy (rarely needed) shows glomerular capillary wall thickening and fibrin thrombi.
F. Genetic Testing: Indicated for aHUS to identify complement factor mutations.
G. Differential Diagnosis: Differentiating from TTP and DIC is critical.

Complete Blood Count (CBC)
Type: Blood Test
Purpose: To evaluate red cell and platelet levels.
Expected Findings: Low Hemoglobin/Hematocrit, Platelet count < 150,000/µL.
Interpretation: Confirms anemia and thrombocytopenia. Peripheral Blood Smear
Type: Blood Test
Purpose: To check for cell morphology.
Expected Findings: Presence of Schistocytes (fragmented RBCs).
Interpretation: Diagnostic for microangiopathic hemolytic anemia. Serum Creatinine and BUN
Type: Blood Test
Purpose: To evaluate renal function.
Expected Findings: Significantly elevated levels.
Interpretation: Indicates acute kidney injury. Serum Lactate Dehydrogenase (LDH)
Type: Blood Test
Purpose: Marker of hemolysis and tissue damage.
Expected Findings: Elevated.
Interpretation: Reflects the severity of intravascular hemolysis. Stool Culture / PCR
Type: Stool Test
Purpose: To identify STEC or Shiga toxin.
Expected Findings: Presence of E. coli O157:H7 or Shiga toxin genes.
Interpretation: Confirms typical STEC-HUS.

• Renal Ultrasound: Used to assess for increased echogenicity and to rule out obstructive uropathy. Normal or slightly enlarged kidneys are typically seen.
• Chest X-ray: Indicated if there are signs of pulmonary edema or fluid overload.
• Brain MRI: Indicated in cases of severe neurological symptoms to check for infarction or edema.

• Thrombotic Thrombocytopenic Purpura (TTP): Characterized by low ADAMTS13 activity; more common in adults; involves more severe neurological signs.
• Disseminated Intravascular Coagulation (DIC): Involves abnormal coagulation studies (elevated PT/PTT), unlike HUS.
• Vasculitis: Often presents with systemic symptoms and specific autoantibodies.

• Chronic Kidney Disease (CKD) and ESRD.
• Cardiovascular: Hypertension, myocardial infarction.
• Neurological: Stroke, encephalopathy, cortical blindness.
• Endocrine: Diabetes mellitus (secondary to pancreatic damage).

A. Lifestyle Modifications: Fluid and electrolyte restriction during the acute phase.
B. Preventive Measures: Strict food hygiene; avoiding antibiotics during the diarrheal phase of STEC (may increase toxin release).
C. Medical Treatment:
| Drug Class | Mechanism | Examples |
| :--- | :--- | :--- |
| Complement Inhibitors | Blocks C5 to prevent MAC formation (for aHUS) | Eculizumab, Ravulizumab |
| Antihypertensives | Manage blood pressure secondary to AKI | Amlodipine, Enalapril |
| IV Fluids | Maintain renal perfusion (early phase) | Isotonic Saline | D. Surgical Treatment: Not typically indicated unless kidney transplant is required for end-stage renal disease.
E. Interventional Procedures:

• Hemodialysis/Peritoneal Dialysis: Required for ~50% of patients during the acute phase.


• Plasmapheresis: Primarily used in aHUS or when TTP is suspected.

The prognosis for STEC-HUS is generally good, with a survival rate >95% in specialized centers. However, 25-30% may develop chronic kidney disease (CKD). Atypical HUS has a much poorer prognosis without complement inhibitor therapy, often progressing to end-stage renal disease (ESRD).

• Cook ground beef to an internal temperature of 160°F (71°C).
• Avoid unpasteurized milk, juice, or cider.
• Wash hands thoroughly after handling raw meat or animal contact.
• Proper sanitation of municipal water supplies.

The following homeopathic remedies have been historically indicated for symptoms associated with Hemolytic Uremic Syndrome. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Hemolytic Uremic Syndrome.